Friday, 29 November 2013

FDA Approves NOXAFIL Delayed Release Tablets - Posaconazole Dosing is Now Once Per Day!

The US drug regulatory body FDA have just approved a new form of the antifungal drug posaconazole that is slowly released into the bloodstream after the patient takes the tablet. This provides two important advantages over the current formulation of posaconazole (which is a liquid that has to be taken by mouth three times a day).




  1. for the most part a single dose is taken per day. This improves convenience for the patient and potentially improves compliancy as it may be more reliable for some people to remember to take a dose once per day
  2. a single dose, slow release regimen encourages a more consistent blood level of the drug and possibly a higher overall blood level
Posaconazole (NOXAFIL) is an important antifungal for the treatment of several forms of aspergillosis and is used as a prophylactic for those patients undergoing treatment that makes them extremely immunocompromised. This improvement in dosing technology will hopefully contribute to improving outcomes in those cases.

The drug is predicted to be available in the second quarter of 2014.

No comments:

Amazon Contextual Product Ads

Contact us at admin@aspergillus.org.uk